PB2128: CELL OF ORIGIN ACCORDING TO HANS LOGARITHM IS AN INDEPENDENT RISK FACTOR FOR DLBCL PATIENTS TREATED WITH R-CHOP: A REAL WORLD MOROCCAN EXPERIENCE

PB2128: CELL OF ORIGIN ACCORDING TO HANS LOGARITHM IS AN INDEPENDENT RISK FACTOR FOR DLBCL PATIENTS TREATED WITH R-CHOP: A REAL WORLD MOROCCAN EXPERIENCE

Bibliographic Details
Main Authors:	E. M. Mahtat, I. Ait Filali, M. Allaoui, S. Jennane, H. El Maaroufi, M. Oukabli, K. Doghmi
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000851344.33425.30

Similar Items

PB2362: THE EFFECT OF BODY MASS INDEX (BMI) ON THE PROGNOSIS OF DLBCL PATIENTS TREATED WITH R-CHOP: A REAL WORLD MOROCCAN EXPERIENCE
by: Imane Ait el Filali, et al.
Published: (2023-08-01)

PB1996: CYTOGENETIC FEATURES OF 164 MOROCCAN PATIENTS WITH MYELODYSPLASTIC SYNDROME
by: Yossra Aghoutane, et al.
Published: (2023-08-01)

PB1784: CYTOGENETIC LANDSCAPE OF 87 MOROCCAN ACUTE MYELOID LEUKEMIA PATIENTS
by: E. M. Mahtat, et al.
Published: (2022-06-01)

P1074: PRIMARY REFRACTORY HODGKIN’S LYMPHOMA: A MOROCCAN MONOCENTRIC RETROSPECTIVE STUDY
by: M. Ababou, et al.
Published: (2022-06-01)

PB2693: ANEMIA IN HEMATOLOGIC MALIGNANCIES: NOT ONLY A SYMPTOM.
by: Oumayma Hari, et al.
Published: (2023-08-01)

PB1839: CYTOGENETIC PROFILE OF ACUTE MYELOBLASTIC LEUKEMIA TREATED AT THE MOHAMMED V MILITARY HOSPITAL IN RABAT (MOROCCO).
by: Moussa Bouh Hawa, et al.
Published: (2023-08-01)

DLBCL 1L—What to Expect beyond R-CHOP?
by: Maike Stegemann, et al.
Published: (2022-03-01)

PB2325: VALIDATION OF THE TRAIL SCORE TO PREDICT TOXICITY IN PATIENTS WITH DLBCL RECEIVING R-CHOP-LIKE THERAPY
by: Juan Carlos Caballero, et al.
Published: (2023-08-01)

Une polyradiculonévrite inflammatoire démyélinisante chronique paranéoplasique secondaire à un lymphome natural killer nasal
by: Selim Jennane, et al.
Published: (2020-08-01)

PB2134: THE ROLE OF ADDITIONAL CARBOGEN GAS MIXTURE AND NICOTINAMIDE ON R-CHOP CHEMOTHERAPY IN DLBCL PATIENTS WITH TUMOR HYPOXIA
by: D. Rizky, et al.
Published: (2022-06-01)

Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL
by: Guido Lancman, et al.
Published: (2018-01-01)

PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
by: Yasmine Moutmir, et al.
Published: (2023-08-01)

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
by: A. Vera de Jonge, et al.
Published: (2023-05-01)

PB2301: OPTIMAL DOSE INTENSITY OF R-CHOP FOR PATIENTS WITH DLBCL AGED 80 YEARS OR OLDER: IS THE R-MINICHOP A GOLD STANDARD?
by: Hironao Nukariya, et al.
Published: (2023-08-01)

CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL
by: Antonin Bouroumeau, et al.
Published: (2021-11-01)

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
by: Hongzhi Geng, et al.
Published: (2023-08-01)

Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP
by: Qian Dong, et al.
Published: (2022-09-01)

PB2131: CLINICAL CHARACTERISTICS AND TREATMENTS OUTCOMES OF PRIMARY GASTROINTESTINAL LYMPHOMA:RETROSPECTIVE SINGLE CENTER STUDY FROM MOROCCO
by: E. Nora, et al.
Published: (2022-06-01)

PB2170: HIGH EXPRESSION OF AP2M1 CORRELATES WITH WORSE PROGNOSIS BY REGULATING IMMUNE MICROENVIRONMENT AND DRUG RESPONSE TO R-CHOP IN DLBCL
by: X.-D. Liu, et al.
Published: (2022-06-01)

Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP–treated DLBCL
by: Antonin Bouroumeau, et al.
Published: (2021-07-01)

CCND2 mRNA Expression Is Correlated With R-CHOP Treatment Efficacy and Prognosis in Patients With ABC-DLBCL
by: Di Wang, et al.
Published: (2020-07-01)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
by: H. Zhu, et al.
Published: (2022-06-01)

Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes
by: Shu Liu, et al.
Published: (2022-03-01)

Mechanisms of linezolid resistance in Staphylococcus capitis with the novel mutation C2128T in the 23S rRNA gene in China
by: Xiao Han, et al.
Published: (2022-08-01)

„Idź i pracuj w mojej winnicy” (Mt 21,28). Praca w przypowieściach Ewangelii synoptycznych
by: Paweł Podeszwa
Published: (2014-06-01)

Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R‐CHOP
by: Eyre, T, et al.
Published: (2019)

PB2128: CLINICAL CONSENSUS ON FIRST-LINE (1L) TREATMENTS FOR TRANSPLANT-INELIGIBLE (TIE) PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): DELPHI PANEL OF US HEMATOLOGISTS AND ONCOLOGISTS
by: Rafael Fonseca, et al.
Published: (2023-08-01)

P1196: ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL
by: Chang-Ju Qu, et al.
Published: (2023-08-01)

The Immunology of DLBCL
by: Taishi Takahara, et al.
Published: (2023-01-01)

PB2379: SPECIFIC ALTERATIONS IN MEMBRANE LIPID LEVELS AS POTENTIAL BIOMARKERS IN DLBCL PATIENTS
by: Federica Loscocco, et al.
Published: (2023-08-01)

Multilingual character recognition dataset for Moroccan official documents
by: Ali Benaissa, et al.
Published: (2024-02-01)

Microtechniques in Pb-U dating of Moroccan zircons.
by: Hull, Marylee Witner
Published: (2010)

DLBCL Coast to Coast
by: Melania Tesio
Published: (2018-02-01)

2128 Using real-time functional magnetic resonance imaging (fMRI) neurofeedback as a tool for demonstrating therapeutic efficacy in cognitive behavioral therapy
by: Kathryn Dickerson, et al.
Published: (2018-06-01)

The Moroccan dialect version of the Insomnia Severity Index
by: Bouchra Oneib, et al.
Published: (2022-02-01)

Meta-analysis DLBCL database
by: Kazmi, F
Published: (2021)

P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL
by: Yan Gao, et al.
Published: (2023-08-01)

Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
by: Kanta Devi, et al.
Published: (2021-01-01)

Tumeur d'Abrikossoff à localisation gastrique: à propos d'un nouveau cas
by: Youssef Hnach, et al.
Published: (2017-11-01)

PB2127: NO IMPACT OF STATIN USE ON RESPONSE AND SURVIVAL RATES IN NEWLY DIAGNOSED DLBCL PATIENTS TREATED WITH R-DA-EPOCH
by: A. Sabljic, et al.
Published: (2022-06-01)